Growth constraints!
There was another promising update from a specialist retailer covered here, which has materially ourperformed its sector in the year to date. While the short-term outlook is favourable, we question the long-term growth potential, as you can discover in our update here. Elsewhere, a highly rated supplier to the NHS is still waiting on approval from the key US market.
Tristel: still waiting on US approval Tristel (AIM: TSTL), the highly-rated manufacturer of infection prevention products for hospitals, announced results for the year ending 30 June 2022. Tristel’s core business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. Reported turnover in the year was flat at £31.1m (2021: £31.0m) although there was 3% growth in continuing products to £29.6m (2021: £28.6m). Overseas sales grew 2% to £20.1m, representing 65% of total sales (2021: 63%),…